| Disease |
| Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
| acute lymphoblastic leukemia |
MassARRAY assay etc. |
acute lymphoblastic leukemia tissue |
differential expression |
mutation |
rs564398 (A>G), mapping to the CDKN2BAS locus that encodes for ANRIL antisense non-coding RNA, showed a statistically significant correlation with the ALL phenotype, with a risk pattern that was compatible with an overdominant model of disease susceptibility. |
21414664 |
LncRNADisease Lnc2Cancer
|
| neurofibromatosis type 1 |
microarray, qPCR etc. |
blood |
up-regulated |
mutation |
Single-nucleotide polymorphism rs2151280 (C>T, located in ANRIL) was statistically significantly associated with the number of PNFs (P < .001) in NF1 patients. In addition, allele T of rs2151280 was statistically significantly associated with reduced ANRIL transcript levels (P < .001), suggesting that modulation of ANRIL expression mediates PNF susceptibility. |
22034633 |
LncRNADisease Lnc2Cancer
|
| type 2 diabetes mellitus |
N/A |
N/A |
N/A |
mutation |
Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs (rs2891168, A>G) in the ANRIL locus on chromosome 9p. |
18048406 |
LncRNADisease
|
| acute lymphoblastic leukemia |
N/A |
N/A |
N/A |
expression |
Higher p15AS levels were often found in acute lymphoblastic (ALL) and myeloid leukemias (AML). |
21874119 |
LncRNADisease
|
| acute myocardial infarction |
N/A |
N/A |
N/A |
N/A |
Level of ANRIL was lower in patients with MI (P=0.003)Patients with ST-segment-elevation MI had lower level of ANRIL (P<0.001)when compared with patients with non-ST-segment-elevation MI. |
25035150 |
LncRNADisease
|
| melanoma |
N/A |
N/A |
N/A |
mutation |
Association identified by GWAS. |
17440112 |
LncRNADisease Lnc2Cancer
|
| type 2 diabetes mellitus |
N/A |
N/A |
N/A |
mutation |
Recent studies showed that single nucleotide polymorphisms (rs3217992, A>G;rs1063192, C>T) mapping in the vicinity of ANRIL are linked to a wide spectrum of conditions, including cardiovascular disease, ischemic stroke, type 2 diabetes, frailty and Alzheimer's disease. |
17463248 |
LncRNADisease
|
| type 2 diabetes mellitus |
N/A |
N/A |
N/A |
mutation |
Association identified by GWAS. |
17463249 |
LncRNADisease
|
| myocardial infarction |
N/A |
N/A |
N/A |
mutation |
Association identified by GWAS. |
17478679 |
LncRNADisease
|
| coronary disease |
N/A |
N/A |
N/A |
mutation |
Association identified by GWAS (rs10757274, A>G;rs2383206, A>G). |
17478681 |
LncRNADisease
|
| coronary artery disease |
N/A |
N/A |
N/A |
mutation |
Sequence polymorphisms in a 58-kilobase (kb) interval on chromosome 9p21 confer a markedly increased risk (rs3217992, A>G;rs1063192, C>T) of coronary artery disease (CAD), the leading cause of death worldwide. |
17554300 |
LncRNADisease
|
| coronary artery disease |
N/A |
N/A |
N/A |
mutation |
Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs (rs2891168, A>G) in the ANRIL locus on chromosome 9p. |
18048406 |
LncRNADisease
|
| Alzheimer's disease |
N/A |
N/A |
N/A |
mutation |
Recent studies showed that single nucleotide polymorphisms (rs3217992, A>G;rs1063192, C>T) mapping in the vicinity of ANRIL are linked to a wide spectrum of conditions, including cardiovascular disease, ischemic stroke, type 2 diabetes, frailty and Alzheimer's disease. |
18761660 |
LncRNADisease
|
| intracranial aneurism |
N/A |
N/A |
N/A |
mutation |
Association identified by GWAS (rs1333040, C>T). |
18997786 |
LncRNADisease
|
| myocardial infarction |
N/A |
N/A |
N/A |
mutation |
association identified by GWAS (rs4977574, A>G). |
19198609 |
LncRNADisease
|
| coronary disease |
N/A |
N/A |
N/A |
locus |
CHD and periodontitis are genetically related by at least one susceptibility locus, which is possibly involved in ANRIL activity and independent of diabetes associated risk variants within this region. Elucidation of the interplay of ANRIL transcript variants and their involvement in increased susceptibility to the interactive diseases CHD and periodontitis promises new insight into the underlying shared pathogenic mechanisms of these complex common diseases. |
19214202 |
LncRNADisease
|
| periodontitis |
N/A |
N/A |
N/A |
locus |
CHD and periodontitis are genetically related by at least one susceptibility locus, which is possibly involved in ANRIL activity and independent of diabetes associated risk variants within this region. Elucidation of the interplay of ANRIL transcript variants and their involvement in increased susceptibility to the interactive diseases CHD and periodontitis promises new insight into the underlying shared pathogenic mechanisms of these complex common diseases. |
19214202 |
LncRNADisease
|
| atherosclerosis |
N/A |
N/A |
N/A |
mutation |
Genotypes of rs10757278 linked to increased risk of atherosclerotic diseases are also associated with decreased expression in PBTL of the INK4/ARF locus, near CDKN2B-AS1 locus. |
19343170 |
LncRNADisease
|
| aortic aneurysm |
N/A |
N/A |
N/A |
expression |
Significantly reduced expression of all INK4/ARF transcripts (p15(INK4b), p16(INK4a), ARF and ANRIL) was found in PBTL of individuals harboring a common SNP (rs10757278) associated with increased risk of coronary artery disease, stroke and aortic aneurysm. |
19343170 |
LncRNADisease
|
| coronary artery disease |
N/A |
N/A |
N/A |
expression |
Significantly reduced expression of all INK4/ARF transcripts (p15(INK4b), p16(INK4a), ARF and ANRIL) was found in PBTL of individuals harboring a common SNP (rs10757278) associated with increased risk of coronary artery disease, stroke and aortic aneurysm. |
19343170 |
LncRNADisease
|
| Stroke |
N/A |
N/A |
N/A |
expression |
Significantly reduced expression of all INK4/ARF transcripts (p15(INK4b), p16(INK4a), ARF and ANRIL) was found in PBTL of individuals harboring a common SNP (rs10757278) associated with increased risk of coronary artery disease, stroke and aortic aneurysm. |
19343170 |
LncRNADisease
|
| glioma |
N/A |
N/A |
N/A |
mutation |
Variants (rs1412829, C>T) in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. |
19578366 |
LncRNADisease
|
| glioma |
N/A |
N/A |
N/A |
mutation |
Association identified by GWAS. |
19578367 |
LncRNADisease
|
| atherosclerosis |
N/A |
N/A |
N/A |
expression |
9p21.3 may promote atherosclerosis by regulating expression of ANRIL, which in turn is associated with altered expression of genes controlling cellular proliferation pathways. |
19592466 |
LncRNADisease
|
| coronary artery disease |
N/A |
N/A |
N/A |
expression |
Whole blood RNA expression of the short variants of ANRIL was increased by 2.2-fold whereas expression of the long ANRIL variant was decreased by 1.2-fold in healthy subjects homozygous for the risk allele. Expression levels of the long and short ANRIL variants were positively correlated with that of the cyclin-dependent kinase inhibitor, CDKN2B (p15) and TDGF1 (Cripto), respectively. |
19592466 |
LncRNADisease
|
| atherosclerosis |
N/A |
N/A |
N/A |
mutation/expression |
Transcripts EU741058 and NR_003529 of antisense noncoding RNA in the INK4 locus (ANRIL) were significantly increased in carriers of the risk haplotype. |
20056914 |
LncRNADisease
|
| intracranial aneurism |
N/A |
N/A |
N/A |
locus |
We also confirmed prior associations near CDKN2A-CDKN2B locus. |
20364137 |
LncRNADisease
|
| coronary disease |
N/A |
N/A |
N/A |
mutation |
Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. |
20386740 |
LncRNADisease Lnc2Cancer
|
| Stroke |
N/A |
N/A |
N/A |
mutation |
Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. |
20386740 |
LncRNADisease Lnc2Cancer
|
| type 2 diabetes mellitus |
N/A |
N/A |
N/A |
mutation |
Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. |
20386740 |
LncRNADisease Lnc2Cancer
|
| familial and sporadic intracranial aneurysms |
N/A |
N/A |
N/A |
mutation |
All 6 index cases from IA families had the rs1333040-T allele (C>T) in CDKN2BAS. |
20395613 |
LncRNADisease
|
| breast cancer |
N/A |
N/A |
N/A |
locus |
A locus associated with breast cancer. |
20453838 |
LncRNADisease
|
| nasopharyngeal carcinoma |
N/A |
N/A |
N/A |
mutation |
A SNP rs1412829 (C49137T) at CDKN2A-CDKN2B gene cluster on 9p21 is associated with this disease. |
20512145 |
LncRNADisease
|
| endometriosis |
N/A |
N/A |
N/A |
mutation |
The authors identified a significant association of endometriosis with rs10965235 (A>C, P = 5.57 x 10(-12), odds ratio = 1.44), which is located in CDKN2BAS on chromosome 9p21, encoding the cyclin-dependent kinase inhibitor 2B antisense RNA.the SNP showing the strongest association was located in intron 16 of CDKN2BAS and was implicated in regulating the expression of p15, p16 and p14. |
20601957 |
LncRNADisease
|
| atherosclerosis |
N/A |
N/A |
N/A |
Interaction |
ANRIL abundantly expressed in atherosclerotic lesions. ANRIL DQ485454 which is not genetically determined by the 9p21 genotype was significantly correlated with MTAP expression. |
20637465 |
LncRNADisease
|
| cardiovascular disease |
N/A |
N/A |
N/A |
mutation |
Recent studies showed that single nucleotide polymorphisms (rs3217992, A>G;rs1063192, C>T) mapping in the vicinity of ANRIL are linked to a wide spectrum of conditions, including cardiovascular disease, ischemic stroke, type 2 diabetes, frailty and Alzheimer's disease. |
20716961 |
LncRNADisease
|
| basal cell carcinoma |
N/A |
N/A |
N/A |
mutation |
More recent GWAS also identified ANRIL as a risk locus (rs3217992, A>G;rs1063192, C>T) for gliomas and basal cell carcinomas in accordance with the princeps observation. |
20956613 |
LncRNADisease
|
| breast cancer |
N/A |
N/A |
N/A |
mutation |
More recently, additional GWAS identified ANRIL as a risk locus (rs3217992, A>G;rs1063192, C>T) for several cancers including breast cancer, nasopharyngeal carcinoma, basal cell carcinoma, and glioma. |
20956613 |
LncRNADisease
|
| coronary disease |
N/A |
N/A |
N/A |
mutation |
Common disease genome wide association studies (GWAS) have surprisingly identified the ANRIL gene as a genetic susceptibility locus (rs3217992, A>G;rs1063192, C>T) shared associated by coronary disease, intracranial aneurysm and also type 2 diabetes. |
20956613 |
LncRNADisease
|
| glioma |
N/A |
N/A |
N/A |
mutation |
More recent GWAS also identified ANRIL as a risk locus (rs3217992, A>G;rs1063192, C>T) for gliomas and basal cell carcinomas in accordance with the princeps observation. |
20956613 |
LncRNADisease
|
| intracranial aneurism |
N/A |
N/A |
N/A |
mutation |
Common disease genomewide association studies (GWAS) have surprisingly identified the ANRIL gene as a genetic susceptibility locus (rs3217992, A>G;rs1063192, C>T)shared associated by coronary disease, intracranial aneurysm and also type 2 diabetes. |
20956613 |
LncRNADisease
|
| nasopharyngeal carcinoma |
N/A |
N/A |
N/A |
mutation |
More recently, additional GWAS identified ANRIL as a risk locus (rs3217992, A>G;rs1063192, C>T) for several cancers including breast cancer, nasopharyngeal carcinoma, basal cell carcinoma, and glioma. |
20956613 |
LncRNADisease
|
| type 2 diabetes mellitus |
N/A |
N/A |
N/A |
mutation |
Common disease genomewide association studies (GWAS) have surprisingly identified the ANRIL gene as a genetic susceptibility locus (rs3217992, A>G;rs1063192, C>T) shared associated by coronary disease, intracranial aneurysm and also type 2 diabetes. |
20956613 |
LncRNADisease
|
| atherosclerosis |
N/A |
N/A |
N/A |
locus |
A genetic susceptibility locus. |
20956613 |
LncRNADisease
|
| basal cell carcinoma |
N/A |
N/A |
N/A |
locus |
A genetic susceptibility locus. |
20956613 |
LncRNADisease
|
| breast cancer |
N/A |
N/A |
N/A |
locus |
A genetic susceptibility locus. |
20956613 |
LncRNADisease
|
| coronary disease |
N/A |
N/A |
N/A |
locus |
A genetic susceptibility locus |
20956613 |
LncRNADisease
|
| glioma |
N/A |
N/A |
N/A |
locus |
A genetic susceptibility locus. |
20956613 |
LncRNADisease
|
| intracranial aneurism |
N/A |
N/A |
N/A |
locus |
A genetic susceptibility locus. |
20956613 |
LncRNADisease
|
| melanoma |
N/A |
N/A |
N/A |
locus |
A genetic susceptibility locus. |
20956613 |
LncRNADisease
|
| nasopharyngeal carcinoma |
N/A |
N/A |
N/A |
locus |
A genetic susceptibility locus. |
20956613 |
LncRNADisease
|
| type 2 diabetes mellitus |
N/A |
N/A |
N/A |
locus |
A genetic susceptibility locus. |
20956613 |
LncRNADisease
|
| abdominal aortic aneurysm |
N/A |
N/A |
N/A |
mutation |
Genetic risk (rs10757278, A>G) for abdominal aortic aneurysm. |
21146954 |
LncRNADisease
|
| cancer |
N/A |
N/A |
N/A |
Interaction |
RNA immunoprecipitation demonstrates that ANRIL binds to SUZ12 in vivo. Collectively, these results suggest a model in which ANRIL binds to and recruits PRC2 to repress the expression of p15(INK4B) locus. |
21151178 |
LncRNADisease
|
| atherosclerosis |
N/A |
N/A |
N/A |
mutation |
Individuals homozygous for the atherosclerotic risk allele (rs3217992, A>G;rs1063192, C>T) show decreased expression of ANRIL. |
21151960 |
LncRNADisease
|
| glaucoma |
N/A |
N/A |
N/A |
mutation |
Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1 (rs4977756, A>G). |
21532571 |
LncRNADisease
|
| atherosclerosis |
N/A |
N/A |
N/A |
expression |
Gene expression studies have found that expression levels of CDKN2A/CDKN2B/ANRIL are co-regulated and associated with the risk haplotype and atherosclerosis severity. |
21550161 |
LncRNADisease
|
| melanoma |
N/A |
N/A |
N/A |
mutation |
A large germline deletion (403231 bp) encompassing the INK4/ARF locus and the ANRIL lncRNA has been associated with hereditary cutaneous malignant melanoma (CMM) and neural system tumors (NST) syndrome. |
21550244 |
LncRNADisease
|
| neural system tumors syndrome |
N/A |
N/A |
N/A |
mutation |
A large germline deletion (403231 bp) encompassing the INK4/ARF locus and the ANRIL lncRNA has been associated with hereditary cutaneous malignant melanoma (CMM) and neural system tumors (NST) syndrome. |
21550244 |
LncRNADisease
|
| Stroke |
N/A |
N/A |
N/A |
mutation |
Variants (rs3217992, A>G;rs1063192, C>T) on chromosome 9p21.3 correlated with ANRIL expression contribute to stroke risk and recurrence in a large prospective stroke population. |
22034006 |
LncRNADisease
|
| peripheral artery disease |
N/A |
N/A |
N/A |
mutation |
SNP rs2383207 on ANRIL was most significantly associated with lower ABI. |
22122968 |
LncRNADisease
|
| atherosclerosis |
N/A |
N/A |
N/A |
mutation |
The risk alleles for atherosclerosis-related phenotypes were consistently associated with a lower expression of ANRIL when evaluating exons 1-2. Common carotid artery stenosis was associated with a significantly lower (P<0.01) expression of ANRIL (exons 1-2). ANRIL knock-down in VSMC caused significant variation in expression of CDKN2A/B (P<0.05) and reduction of cell growth (P<0.05) in vitro. |
22178423 |
LncRNADisease
|
| glioma |
N/A |
N/A |
N/A |
mutation |
Moreover, genome-wide association studies have demonstrated that the 9p21 genomic locus is a hotspot for the risk of stroke, glioma, plexiform neurofibroma and other disorders |
22814587 |
LncRNADisease
|
| plexiform neurofibroma |
N/A |
N/A |
N/A |
mutation |
Moreover, genome-wide association studies have demonstrated that the 9p21 genomic locus is a hotspot for the risk of stroke, glioma, plexiform neurofibroma and other disorders |
22814587 |
LncRNADisease
|
| Stroke |
N/A |
N/A |
N/A |
mutation |
Moreover, genome-wide association studies have demonstrated that the 9p21 genomic locus is a hotspot for the risk of stroke, glioma, plexiform neurofibroma and other disorders |
22814587 |
LncRNADisease
|
| acute lymphoblastic leukemia |
N/A |
N/A |
N/A |
expression |
Disruptions to the expression of ANRIL have accordingly been associated with the development of several cancer types, including neuroblastoma , acute lymphocytic leukaemia, melanoma and prostate |
22817756 |
LncRNADisease
|
| melanoma |
N/A |
N/A |
N/A |
expression |
Disruptions to the expression of ANRIL have accordingly been associated with the development of several cancer types, including neuroblastoma , acute lymphocytic leukaemia, melanoma and prostate |
22817756 |
LncRNADisease
|
| neuroblastoma |
N/A |
N/A |
N/A |
expression |
Disruptions to the expression of ANRIL have accordingly been associated with the development of several cancer types, including neuroblastoma , acute lymphocytic leukaemia, melanoma and prostate |
22817756 |
LncRNADisease
|
| prostate cancer |
N/A |
N/A |
N/A |
expression |
Disruptions to the expression of ANRIL have accordingly been associated with the development of several cancer types, including neuroblastoma , acute lymphocytic leukaemia, melanoma and prostate |
22817756 |
LncRNADisease
|
| Stroke |
N/A |
N/A |
N/A |
expression |
Genetic variants that affect the expression of the ANRIL transcript have been correlated with stroke risk and recurrence in a large prospective study |
22817756 |
LncRNADisease
|
| cancer |
N/A |
N/A |
N/A |
mutation |
Interestingly, genome wide association studies (GWAS) identified several variants in the intergenic region encompassing ANRIL to be associated with several diseases such as coronary heart disease, intracranial aneurysm, many type of cancers and T4D |
22928560 |
LncRNADisease
|
| coronary disease |
N/A |
N/A |
N/A |
mutation |
Interestingly, genome wide association studies (GWAS) identified several variants in the intergenic region encompassing ANRIL to be associated with several diseases such as coronary heart disease, intracranial aneurysm, many type of cancers and T2D |
22928560 |
LncRNADisease
|
| intracranial aneurism |
N/A |
N/A |
N/A |
mutation |
Interestingly, genome wide association studies (GWAS) identified several variants in the intergenic region encompassing ANRIL to be associated with several diseases such as coronary heart disease, intracranial aneurysm, many type of cancers and T3D |
22928560 |
LncRNADisease
|
| type 2 diabetes mellitus |
N/A |
N/A |
N/A |
mutation |
Interestingly, genome wide association studies (GWAS) identified several variants in the intergenic region encompassing ANRIL to be associated with several diseases such as coronary heart disease, intracranial aneurysm, many type of cancers and T5D |
22928560 |
LncRNADisease
|
| leukemia |
N/A |
N/A |
N/A |
regulation |
Gene silencing of INK4b-ARF-INK4a and p15/CDKN2B by recruitment of PRC1 and PRC2. |
22996375 |
LncRNADisease
|
| prostate cancer |
N/A |
N/A |
N/A |
regulation |
Gene silencing of INK4b-ARF-INK4a and p15/CDKN2B by recruitment of PRC1 and PRC2. |
22996375 |
LncRNADisease
|
| cancer |
N/A |
N/A |
N/A |
expression |
ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. |
23104877 |
LncRNADisease
|
| cardiovascular disease |
N/A |
N/A |
N/A |
expression |
ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. |
23104877 |
LncRNADisease
|
| coronary artery disease |
N/A |
N/A |
N/A |
expression |
However, overexpression of 1 ANRIL variant altered the expression of many genes involved in nuclear regulation and chromatin architecture, indicating diverse trans-regulatory effects that go beyond the cis-effects seen at 9p21. |
23104877 |
LncRNADisease
|
| diabetes mellitus |
N/A |
N/A |
N/A |
expression |
ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. |
23104877 |
LncRNADisease
|
| endometriosis |
N/A |
N/A |
N/A |
expression |
ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. |
23104877 |
LncRNADisease
|
| glaucoma |
N/A |
N/A |
N/A |
expression |
ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. |
23104877 |
LncRNADisease
|
| glaucoma |
N/A |
N/A |
N/A |
mutation |
CDKN2B-AS1 genotype-glaucoma feature correlations in primary open-angle glaucoma patients from the United States. |
23111177 |
LncRNADisease
|
| prostate cancer |
N/A |
N/A |
N/A |
expression |
ANRIL, also upregulated in prostate cancer, is required for the repression of the tumor suppressors INK4a/p16 and INK4b/p15. |
23463798 |
LncRNADisease
|
| cancer |
N/A |
N/A |
N/A |
expression |
Another lncRNA associated with human cancers is ANRIL, a long, antisense transcript found in the INK4a/Arf locus. ANRIL is overexpressed in human leukemias and prostate cancers, and its expression leads to epigenetic silencing of the nearby tumor suppressor p15 (Yu et al., 2008; Yap et al., 2010). |
23473599 |
LncRNADisease
|
| prostate cancer |
N/A |
N/A |
N/A |
expression |
Recent studies have linked their mis-expression to diverse cancers (ANRIL: prostate cancer, XIST: female cancers, HOTAIR: breast cancer, KCNQ1OT1: colorectal cancer). |
23660942 |
LncRNADisease
|
| Alzheimer's disease |
N/A |
N/A |
N/A |
mutation |
Genetic variation in lncRNA genes causes disease and influences susceptibility |
23791884 |
LncRNADisease
|
| atherosclerosis |
N/A |
N/A |
N/A |
mutation |
Genetic variation in lncRNA genes causes disease and influences susceptibility |
23791884 |
LncRNADisease
|
| diabetes mellitus |
N/A |
N/A |
N/A |
mutation |
Genetic variation in lncRNA genes causes disease and influences susceptibility |
23791884 |
LncRNADisease
|
| glaucoma |
N/A |
N/A |
N/A |
mutation |
Genetic variation in lncRNA genes causes disease and influences susceptibility |
23791884 |
LncRNADisease
|
| glioma |
N/A |
N/A |
N/A |
mutation |
Genetic variation in lncRNA genes causes disease and influences susceptibility |
23791884 |
LncRNADisease
|
| intracranial aneurism |
N/A |
N/A |
N/A |
mutation |
Genetic variation in lncRNA genes causes disease and influences susceptibility |
23791884 |
LncRNADisease
|
| plexiform neurofibroma |
N/A |
N/A |
N/A |
mutation |
Genetic variation in lncRNA genes causes disease and influences susceptibility |
23791884 |
LncRNADisease
|
| Stroke |
N/A |
N/A |
N/A |
mutation |
Genetic variation in lncRNA genes causes disease and influences susceptibility |
23791884 |
LncRNADisease
|
| atherosclerosis |
N/A |
N/A |
N/A |
regulation |
The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. |
23813974 |
LncRNADisease
|
| cancer |
N/A |
N/A |
N/A |
regulation |
The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. |
23813974 |
LncRNADisease
|
| periodontitis |
N/A |
N/A |
N/A |
regulation |
The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. |
23813974 |
LncRNADisease
|
| atherosclerosis |
N/A |
N/A |
N/A |
mutation |
Chr9p21 encodes the long non-coding RNA (ncRNA) antisense non-coding RNA in the INK4 locus (ANRIL). ANRIL expression is associated with the Chr9p21 genotype and correlated with atherosclerosis severity |
23861667 |
LncRNADisease
|
| cardiovascular disease |
N/A |
N/A |
N/A |
regulation |
Recently, ANRIL, a multi-exonic lncRNA, has been shown to be implicated in epigenetic modulation in cardiac development and adult heart and also it has been associated with a locus implicated in cardiovascular disease. |
24113581 |
LncRNADisease
|
| Stroke |
N/A |
N/A |
N/A |
expression |
Levels of CDKN2B-AS1/ANRIL in human carotid atherosclerotic plaques and peripheral blood T lymphocytes are linked to rates of ischemic and hemorrhagic stroke. |
24145019 |
LncRNADisease
|
| prostate cancer |
N/A |
N/A |
N/A |
regulation |
ANRIL is an antisense lncRNA elevated in PCa that overlaps this locus, interacting directly with polycomb repressive complex 1 and histone H3K27 methylation to repress CDKN2A-CDKN2B expression |
24146262 |
LncRNADisease
|
| ischemic stroke |
N/A |
N/A |
N/A |
regulation |
Regulation of CARD8 expression by ANRIL and association of CARD8 single nucleotide polymorphism rs2043211 (p.C10X) with ischemic stroke. |
24385277 |
LncRNADisease
|
| cardiovascular disease |
N/A |
N/A |
N/A |
mutation |
Aberrant ANRIL transcripts and mutations were associated with cardiovascular disease and cancer . |
24531795 |
LncRNADisease
|
| cardiovascular disease |
N/A |
N/A |
N/A |
mutation |
Aberrant ANRIL transcripts and mutations were associated with cardiovascular disease and cancer . |
24531795 |
LncRNADisease
|
| hereditary cutaneous malignant melanoma |
N/A |
N/A |
N/A |
N/A |
Long ncRNA antisense non-coding RNA in the INK4 locus (ANRIL) has been associated to hereditary cutaneous malignant melanoma, prostate cancer and tumors of the neural system (Pasmant et al., 2011). |
24624135 |
LncRNADisease
|
| prostate cancer |
N/A |
N/A |
N/A |
N/A |
Long ncRNA antisense non-coding RNA in the INK4 locus (ANRIL) has been associated to hereditary cutaneous malignant melanoma, prostate cancer and tumors of the neural system (Pasmant et al., 2011). |
24624135 |
LncRNADisease
|
| tumor |
N/A |
N/A |
N/A |
N/A |
Long ncRNA antisense non-coding RNA in the INK4 locus (ANRIL) has been associated to hereditary cutaneous malignant melanoma, prostate cancer and tumors of the neural system (Pasmant et al., 2011). |
24624135 |
LncRNADisease
|
| cancer |
N/A |
N/A |
N/A |
locus |
Furthermore, genome wide association studies have identified the ANRIL gene as a risk locus for coronary disease, intracranial aneurism, type 2 diabetes and several cancers including glioma. |
24624135 |
LncRNADisease
|
| coronary disease |
N/A |
N/A |
N/A |
locus |
Furthermore, genome wide association studies have identified the ANRIL gene as a risk locus for coronary disease, intracranial aneurism, type 2 diabetes and several cancers including glioma. |
24624135 |
LncRNADisease
|
| intracranial aneurism |
N/A |
N/A |
N/A |
locus |
Furthermore, genome wide association studies have identified the ANRIL gene as a risk locus for coronary disease, intracranial aneurism, type 2 diabetes and several cancers including glioma. |
24624135 |
LncRNADisease
|
| type 2 diabetes mellitus |
N/A |
N/A |
N/A |
locus |
Furthermore, genome wide association studies have identified the ANRIL gene as a risk locus for coronary disease, intracranial aneurism, type 2 diabetes and several cancers including glioma. |
24624135 |
LncRNADisease
|
| tumor |
N/A |
N/A |
N/A |
regulation |
ANRIL, GAS5 and lincRNA-p23 are involved in the escape of growth suppression by regulating tumor suppressor genes (ANRIL) or apoptosis regulators. |
24667321 |
LncRNADisease
|
| prostate cancer |
N/A |
N/A |
N/A |
expression |
ANRIL is upregulated in prostate cancer and is required for the repression of the tumor suppressors INK4a/p16 and INK4b/p15 (Yap et al., 2010; Kotake et al., 2011). |
24721780 |
LncRNADisease
|
| cancer |
N/A |
N/A |
N/A |
expression |
High expression of ANRIL has been found in certain cancer tissues such as melanoma and prostate cancers? |
24757675 |
LncRNADisease
|
| nasopharyngeal carcinoma |
N/A |
N/A |
N/A |
mutation |
In recent years, GWAS has identified ANRIL as a risk locus for NPC and other cancers. |
24817925 |
LncRNADisease
|
| cancer |
N/A |
N/A |
N/A |
regulation |
It has also been shown that the tumor suppressor gene p15 is silenced by its natural antisense RNA, a lncRNA ANRIL. |
24829860 |
LncRNADisease
|
| endometriosis |
N/A |
N/A |
N/A |
mutation |
Rs10965235 SNP in the CDKN2B-AS gene was significantly associated with endometriosis in this Korean population. |
25154675 |
LncRNADisease
|
| breast cancer |
qPCR etc. |
breast cancer tissue |
up-regulated |
expression |
Expression of ANRIL mainly coclustered with p14/ARF both in physiologic (various normal human tissues) and in pathologic conditions (human breast tumors). |
17440112 |
LncRNADisease Lnc2Cancer
|
| melanoma |
qPCR etc. |
melanoma tissue |
differential expression |
mutation |
Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. |
20386740 |
LncRNADisease Lnc2Cancer
|
| glioma |
qPCR etc. |
glioma tissue |
differential expression |
mutation |
Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. |
20386740 |
LncRNADisease Lnc2Cancer
|
| prostate cancer |
qPCR etc. |
cell lines (PC3, MEFs, IMR90 etc.) |
up-regulated |
Interaction |
Here we report that chromobox 7 (CBX7) within the polycomb repressive complex 1 binds to ANRIL, and both CBX7 and ANRIL are found at elevated levels in prostate cancer tissues. |
20541999 |
LncRNADisease Lnc2Cancer
|
| cervical cancer |
qPCR etc. |
cell line (CaSki) |
up-regulated |
expression |
Down-regulated in cells were incubated in the presence of BLM for 24 h or irradiated. |
22487937 |
LncRNADisease Lnc2Cancer
|
| laryngeal squamous cell carcinoma |
qPCR etc. |
LSCC tissue |
up-regulated |
expression |
We discovered that five lncRNAs were differentially expressed between primary LSCC samples and adjacent normal tissues. Among them, three lncRNAs were up-expressed in tumor specimens, including CDKN2B-AS1, HOTAIR and MALAT1. More, two lncRNAs had significant down-expression, which were lncRNA RRP1B and SRA1. Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. |
25257554 |
Lnc2Cancer
|
| acute lymphoblastic leukemia |
qPCR, knockdown etc. |
cell lines (KG-1, Kasumi-1) |
up-regulated |
N/A |
We found an inverse relation between p15 antisense (p15AS) and p15 sense expression in leukaemia. A p15AS expression construct induced p15 silencing in cis and in trans through heterochromatin formation but not DNA methylation; the silencing persisted after p15AS was turned off, although methylation and heterochromatin inhibitors reversed this process. Moreover, 11 out of 16 patient samples (69%) showed relatively increased expression of p15AS and downregulated p15 expression (6/11 in acute myeloid leukaemia and 5/5 in acute lymphoblastic leukaemia). In contrast, 16 normal controls showed high expression of p15 but relatively low expression of the p15AS. Additionally, the two acute myeloid leukaemia lines, which displayed high p15AS and low p15 expression. |
18185590 |
Lnc2Cancer
|
| acute myeloid leukemia |
qPCR, knockdown etc. |
cell lines (KG-1, Kasumi-1) |
up-regulated |
N/A |
We found an inverse relation between p15 antisense (p15AS) and p15 sense expression in leukaemia. A p15AS expression construct induced p16 silencing in cis and in trans through heterochromatin formation but not DNA methylation; the silencing persisted aftp15AS was turned off, although methylation and heterochromatin inhibitors reversed this process. Moreover, 11 out of 16 patient samples (69%) showed relatively increased expression of p15AS and downregulated p15 expression (6/11 in acute myeloid leukaemia and 5/5 in acute lymphoblastic leukaemia). In contrast, 16 normal controls showed high expression of p15 but relatively low expression of the p15AS. Additionally, the two acute myeloid leukaemia lines, which displayed high p15AS and low p15 expression.on. |
18185590 |
Lnc2Cancer
|
| hepatocelluar carcinoma |
qPCR, knockdown etc. |
HCC tissue, cell lines ((HepG2 etc.) |
up-regulated |
expression |
LncRNA ANRIL expression in HCC tissues was significantly higher than in the adjacent non-tumor tissues (P < 0.05). The expression of lncRNA ANRIL was remarkably associated with the histologic grade and TNM stage of HCC patients (P < 0.05). In addition, HCC patients with higher lncRNA ANRIL expression had significantly poorer overall survival (P < 0.05).Moreover, in vitro assays revealed that the decreased expression of lncRNA ANRIL could suppress the cell proliferation, migration and invasion HCC cells. |
26045820 |
Lnc2Cancer
|
| cervical cancer |
qPCR, knockdown etc. |
cell lines (HeLa) |
up-regulated |
interaction |
qRT-PCR showed that ANRIL is highly expressed in these cancer cells compared to normal fibroblasts. Depletion of ANRIL increased p15 expression, with no impact on p16 or ARF (alternative reading frame) expression, and caused cell-cycle arrest at the G2/M phase, leading to inhibition of proliferation of H1299 and HeLa cells. |
26408699 |
Lnc2Cancer
|
| non-small cell lung cancer |
qPCR, knockdown etc. |
cell lines (ABC-1, H1299) |
up-regulated |
expression |
qRT-PCR showed that ANRIL is highly expressed in these cancer cells compared to normal fibroblasts. Depletion of ANRIL increased p15 expression, with no impact on p16 or ARF (alternative reading frame) expression, and caused cell-cycle arrest at the G2/M phase, leading to inhibition of proliferation of H1299 and HeLa cells. |
26408699 |
Lnc2Cancer
|
| osteosarcoma |
qPCR, knockdown etc. |
cell lines (Saos-2) |
up-regulated |
expression |
qRT-PCR showed that ANRIL is highly expressed in these cancer cells compared to normal fibroblasts. Depletion of ANRIL increased p15 expression, with no impact on p16 or ARF (alternative reading frame) expression, and caused cell-cycle arrest at the G2/M phase, leading to inhibition of proliferation of H1299 and HeLa cells. |
26408699 |
Lnc2Cancer
|
| non-small cell lung cancer |
qPCR, Western blot etc. |
NSCLC tissue, cell lines (PC9, SPC-A1, NCI-H1975, H1299, H358) |
up-regulated |
expression |
In this study, we reported that ANRIL expression was increased in NSCLC tissues and Its expression level was significantly correlated with TNM stages and tumor size. Moreover, patients with high levels of ANRIL expression had a relatively poor prognosis. In addition, taking advantage of loss of function experiments in NSCLC cells, we found that knockdown of ANRIL expression could impair cell proliferation and induce cell apoptosis both in vitro and vivo. |
25504755 |
Lnc2Cancer
|
| bladder cancer |
qPCR, Western blot etc. |
bladder cancer specimens and the corresponding adjacent non-tumor tissues |
up-regulated |
interaction |
Our results showed up-regulation of ANRIL in bladder cancer tissues versus the corresponding adjacent non-tumor tissues. Knockdown of ANRIL repressed cell proliferation and increased cell apoptosis, along with decreased expression of Bcl-2 and increased expressions of Bax, cytoplasmic cytochrome c and Smac and cleaved caspase-9, caspase-3 and PARP. |
26449463 |
Lnc2Cancer
|
| esophageal squamous cell carcinoma |
qPCR, Western blot, knockdown etc. |
ESCC tissue, cell lines (TE1, ECA109) |
up-regulated |
regulation |
ANRIL inhibits p15INK4b through the TGFβ1 signaling pathway in human esophageal squamous cell carcinoma. |
24747824 |
LncRNADisease Lnc2Cancer
|
| serous ovarian cancer |
qPCR, Western blot, knockdown etc. |
SOC tissue, cell lines (SK-OV-3, HO8910) |
up-regulated |
interaction |
We found that ANRIL levels were elevated in SOC tissues compared with normal controls and were highly correlated with advanced FIGO stage, high histological grade, lymph node metastasis, and poor prognosis. Functional studies suggest a critical role of ANRIL in the control of SOC cell migration/invasion at least in part through regulation of MET and MMP3. |
25845387 |
Lnc2Cancer
|
| gastric cancer |
qPCR, Western blot, knockdown, RIP etc. |
gastric cancer tissue, cell lines (SGC7901, BGC823, MGC803) |
up-regulated |
regulation |
Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. |
24810364 |
LncRNADisease Lnc2Cancer
|
| hepatocelluar carcinoma |
qPCR, Western blot, knockdown, RIP etc. |
HCC tissue, cell lines (HepG2, Hep3B, MHCC-97H) |
up-regulated |
interaction |
ANRIL expression was up-regulated in HCC tissues, and the higher expression of ANRIL was significantly correlated with tumor size and Barcelona Clinic Liver Cancer (BCLC) stage. Moreover, taking advantage of loss of function experiments in HCC cells, we found that knockdown of ANRIL expression could impair cell proliferation and invasion and induce cell apoptosis both in vitro and in vivo. |
25966845 |
Lnc2Cancer
|
| non-small cell lung cancer |
qRT-PCR |
87 NSCLC tissues and three lung cancer cell lines |
up-regulated |
expression |
The expression level of lncRNA ANRIL was higher in NSCLC tissues and lung cancer cells than in adjacent non-tumor tissues and normal human bronchial epithelial cells. Higher expression of lncRNA ANRIL in NSCLC tissues was associated with higher TNM stage and advanced lymph node metastasis. Our results suggested that lncRNA ANRIL was a potential biomarker for NSCLC prognosis. |
25889788 |
|
| non-small-cell lung cancer |
qRT-PCR |
patients suffering from non-small-cell lung cancer (NSCLC) |
up-regulated |
expression |
N/A |
26448925 |
|
| invasive breast carcinomas |
qRT-PCR and immunohistochemistry (IHC) |
invasive breast carcinomas |
N/A |
N/A |
N/A |
27102007 |
|
| gastric cancer |
silencing ; qRT-PCR and western blotting |
gastric cancer tissues of cisplatin-resistant and 5-fluorouracil (5-FU)-resistant patients |
up-regulated |
N/A |
ANRIL positively correlated with the expression in gastic cell; silencing ANRIL decreased the IC50 values in gastric cancer cells |
27121324 |
|
| |